Nanodelivery of drugs for therapeutic strategies in CNS disorders. Current and Future perspectives

by Sharma, Aruna; Muresanu, Dafin F.; Lafuente, Jose Vicente; Patnaik, Ranjana; Tian, Z. Ryan; Ozikzilcik, Asya; Mossier, Herbert; Sharma, Hari S.

In this innovation, we examined sleep deprivation (SD) induced brain pathology and therapeutic strategies to induce neuroprotction using nanodelivery of cerebrolysin. SD is a serious problem in military and we have previously shown that SD of 12 to 48 h causes blood-brain barrier (BBB) disruption, brain edema formation and neuronal damages after 48 h SD. Measurement of BDNF showed 50 to 60 % decline in different brain areas in SD. Nanowired delivery of cerebrolysin 4 to 6 h after the onset of SD significantly reduced brain pathology and enhanced regional BDNF levels after 48 h SD. However, normal cerebrolysin given after the onset of SD has only minimal effects on regional BDNF level and brain pathology seen at 48 h SD. This indicates that nanodelivery of drugs have superior effects in achieving neuroprotection. Thus, we feel that our policy makers, researchers, clinicians and nanotechnologists should consider exploring the dose response relationship of nanoparticles from wide variety of nanocarriers on cellular toxicity both in vivo and in vitro situations urgently. These studies will help create a database for suitable nanocarriers to use for drug delivery to the CNS as effective therapeutic tools for clinical practice. Only after these data, nanoneuropharmacology could be developed as a distinct discipline in the near future.

10th Annual TechConnect World Innovation Conference and Expo, Held Jointly with the 19th Annual Nanotech Conference and Expo, and the 2016 National SBIR/STTR Conference